Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety-Reference-Cited by-同舟云学术

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

Published:2021-08 Issue:6 Volume:5 Page:
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Mahlangu Johnny¹,Levy Howard²,Kosinova Marina V.³,Khachatryan Heghine⁴,Korczowski Bartosz⁵,Makhaldiani Levani⁶,Iosava Genadi⁷,Lee Martin⁸,Del Greco Frank²

Affiliation:

1. Haemophilia Comprehensive Care CenterCharlotte Maxeke Johannesburg Academic HospitalUniversity of the Witwatersrand and NHLS Johannesburg South Africa

2. Catalyst Biosciences South San Francisco CA USA

3. Hematology Kemerovo Regional Clinical Hospital Kemerovo Russia

4. R.H. Yeolyan Hemophilia and Thrombophilia Center Yerevan Republic of Armenia

5. Institute of Medical Sciences College of Medical Sciences of the University of Rzeszow, University of Rzeszow Rzeszow Poland

6. K. Eristavi National Center of Experimental and Clinical Surgery Tbilisi Georgia

7. Institute of Hematology and Transfusiology Tbilisi Georgia

8. Fielding School of Public Health University of California Los Angeles Los Angeles CA USA

Funder

Catalyst Biosciences

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12576

Reference40 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. Gene Therapy for Hemophilia

3. The past and future of haemophilia: diagnosis, treatments, and its complications

4. Clinical issues in inhibitors

5. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors;Clinical Pharmacology & Therapeutics;2024-01-16

2. Recombinant Coagulation Factors and Thrombolytic Agents;Pharmaceutical Biotechnology;2024

3. Gene therapy for hemophilia, a clinical viewpoint;Journal of the Formosan Medical Association;2023-11

4. Clinical pharmacology of emicizumab for the treatment of hemophilia A;Expert Review of Clinical Pharmacology;2023-08-21

5. Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy;CPT: Pharmacometrics & Systems Pharmacology;2023-05-02